Published on 1 Mar 2023 on Simply Wall St. via Yahoo Finance
Ocugen, Inc. (NASDAQ:OCGN): Is Breakeven Near?
With the business potentially at an important milestone, we thought we'd take a closer look at Ocugen, Inc.'s (NASDAQ:OCGN) future prospects. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The US$226m market-cap company announced a latest loss of US$81m on 31 December 2022 for its most recent financial year result. Many investors are wondering about the rate at which Ocugen will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Check out our latest analysis for Ocugen